Heterologous Gene Therapy for Metabolism

Harding, Cary O.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Type: Clinical Investigator Award (CIA) (K08)
• Project #: 1K08DK002405-01
• Application #: 2134351
• Study Section: Special Emphasis Panel (SRC)
• Project Start: 1996-02-01
• Project End: 2001-01-31
• Budget Start: 1996-02-01
• Budget End: 1997-01-31
• Support Year: 1
• Fiscal Year: 1996

Institution

• Name: University of Wisconsin Madison
• Department: Pediatrics
• Type: Schools of Medicine
• DUNS #: 161202122
• City: Madison
• State: WI
• Country: United States
• Zip Code: 53715

Publications

Hamman, Kelly; Clark, Heather; Montini, Eugenio et al. (2005) Low therapeutic threshold for hepatocyte replacement in murine phenylketonuria. Mol Ther 12:337-44

Harding, Cary O; Neff, Mark; Wild, Krzysztof et al. (2004) The fate of intravenously administered tetrahydrobiopterin and its implications for heterologous gene therapy of phenylketonuria. Mol Genet Metab 81:52-7

Harding, Cary O; Neff, Mark; Jones, Kelly et al. (2003) Expression of phenylalanine hydroxylase (PAH) in erythrogenic bone marrow does not correct hyperphenylalaninemia in Pah(enu2) mice. J Gene Med 5:984-93

Harding, C O; Wild, K; Chang, D et al. (1998) Metabolic engineering as therapy for inborn errors of metabolism--development of mice with phenylalanine hydroxylase expression in muscle. Gene Ther 5:677-83